Trial record 1 of 54 for:
"Asperger syndrome"
Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
This study is currently recruiting participants.
Verified May 2013 by Montefiore Medical Center
Sponsor:
Montefiore Medical Center
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
Eric Hollander, Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT01337700
First received: December 27, 2010
Last updated: May 30, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Autism Spectrum Disorders (ASD) include Autistic disorder, Asperger's syndrome and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). These are developmental disorders beginning prior to three years of age. Recent Centers for Disease Control (CDC) estimates suggest that ASD affects up to 1 in 100 individuals and up to 1 in 50 boys. There are very substantial costs associated with caring for patients with ASD, and ASD has the highest Caregiver Burden Scores of any condition. There are three core symptom domains of ASD, including social deficits, repetitive behaviors and language deficits. Patients can also have associated symptoms of attentional deficits, disruptive behaviors and intellectual disability. There is currently no Food and Drug administration (FDA) approved treatment for the core symptoms of autism, but risperidone and aripiprazole have FDA approval for disruptive behaviors associated with autism.
This is a 12 week randomized double blind placebo controlled trial of Milnacipran in adults with ASD or Aspergers Syndrome. Milnacipran is said to play a role in the activation and normalization of the locus coeruleus-noradrenergic system, of which is hypothesized to play a role in behavior adaptations and performance.
| Condition | Intervention | Phase |
|---|---|---|
|
Autism Spectrum Disorder Asperger Syndrome Aspergers Syndrome |
Drug: Milnacipran Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism |
Resource links provided by NLM:
Further study details as provided by Montefiore Medical Center:
Primary Outcome Measures:
- Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale [ Time Frame: Baseline through Week 12 ] [ Designated as safety issue: No ]Change will be measured in each subject's score on the Conners from baseline through study end (week 12). It is a clinically expert rating scale used to measure attention dysfunction. It offers good psychometric properties and psychopathological item content focused on inattention, impulsivity and hyperactivity. Change in subjects on placebo, will be compared to those receiving the study drug.
Secondary Outcome Measures:
- Aberrant Behavior Checklist - Irritability Scale [ Time Frame: Screening, baseline, weeks 2,4,6,8,10,12 ] [ Designated as safety issue: No ]Rating scale sensitive to changes in disruptive behaviors in autism.
- Yale-Brown Obsessive Compulsive Scale (YBOCS)- Compulsion Subscale [ Time Frame: screening, baseline, weeks, 2,4,6,8,10,12 ] [ Designated as safety issue: No ]Clinical tool used to measure repetitive behaviors in autism trials.
- Diagnostic Analysis of Nonverbal Activity-2 (DANVA-2) [ Time Frame: screening, baseline, weeks 2,4,6,8,10,12 ] [ Designated as safety issue: No ]Tool used to measure social cognition in adults with autism, as related to amygdala function.
- NoGo-Go Task During functional Magnetic Resonance Imaging (fMRI) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]A neurocognitive task of motor inhibition measured during the fMRI.
- Core Autism Treatment Scale - Severity and Improvement [ Time Frame: screening, baseline, weeks 2, 4, 6, 8, 10, 12 ] [ Designated as safety issue: No ]Tool used to compare pretreatment ratings of severity and post treatment ratings of improvement after the start of therapy.
- Clinical Global Impressions Scale (CGI) [ Time Frame: screening, baseline, weeks 2,4,6,8,10,12 ] [ Designated as safety issue: No ]A scale that measures improvement based off of the clinician's interpretations.
| Estimated Enrollment: | 34 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Milnacipran |
Drug: Milnacipran
Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
Other Name: Savella
|
| Placebo Comparator: Placebo |
Drug: Placebo
Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and Female patients
- Aged 18-50 years
- Diagnosis of Autism Spectrum Disorder
- IQ greater than 70
Exclusion Criteria:
- Pregnant subjects
- Patients deemed by comprehensive psychiatric interview to have a significant risk of suicide
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01337700
Contacts
| Contact: Casara J Ferretti, MS | 718-696-3036 | cferrett@montefiore.org |
| Contact: Emma Racine, BA | 718-653-4859 ext 223 | eracine@montefiore.org |
Locations
| United States, New York | |
| Montefiore Medical Center, Albert Einstein College of Medicine | Recruiting |
| Bronx, New York, United States, 10467 | |
| Contact: Casara J Ferretti, MS 718-696-3036 cferrett@montefiore.org | |
| Principal Investigator: Eric Hollander, MD | |
Sponsors and Collaborators
Montefiore Medical Center
Forest Laboratories
Investigators
| Principal Investigator: | Eric Hollander, MD | Montefiore Medical Center, Albert Einstein College of Medicine |
More Information
No publications provided
| Responsible Party: | Eric Hollander, Clinical Professor, Montefiore Medical Center |
| ClinicalTrials.gov Identifier: | NCT01337700 History of Changes |
| Other Study ID Numbers: | SAV-MD-21, 10-09-299 |
| Study First Received: | December 27, 2010 |
| Last Updated: | May 30, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Montefiore Medical Center:
|
ASD Autism Autism Spectrum Disorder Asperger Syndrome |
Asperger PDD PDD-NOS |
Additional relevant MeSH terms:
|
Asperger Syndrome Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders Milnacipran Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses |
Pharmacologic Actions Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents |
ClinicalTrials.gov processed this record on June 17, 2013